OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $25.38 and last traded at $25.2860, with a volume of 78942 shares changing hands. The stock had previously closed at $24.70.

Analysts Set New Price Targets

A number of brokerages have recently commented on KIDS. Piper Sandler reissued an "overweight" rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Needham & Company LLC raised their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research reaffirmed a "buy" rating and issued a $24.00 price target on shares of OrthoPediatrics in a research note on Friday, May 1st. Finally, Weiss Ratings upgraded shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.89.

Read Our Latest Report on OrthoPediatrics

OrthoPediatrics Trading Up 3.1%

The company has a fifty day simple moving average of $20.23 and a 200-day simple moving average of $18.17. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The stock has a market cap of $664.68 million, a price-to-earnings ratio of -15.14 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $70.51 million during the quarter, compared to analysts' expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. On average, research analysts forecast that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of OrthoPediatrics during the 2nd quarter valued at $24,347,000. Millennium Management LLC increased its holdings in OrthoPediatrics by 48.0% in the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company's stock worth $24,802,000 after buying an additional 452,840 shares during the last quarter. AIGH Capital Management LLC bought a new position in OrthoPediatrics during the second quarter valued at approximately $5,161,000. AWM Investment Company Inc. acquired a new stake in shares of OrthoPediatrics in the second quarter worth about $4,537,000. Finally, Granahan Investment Management LLC lifted its holdings in OrthoPediatrics by 35.1% in the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company's stock worth $14,231,000 after purchasing an additional 232,760 shares during the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

(Get Free Report)

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

Recommended Stories

• Five stocks we like better than OrthoPediatrics
• The AI Boom Is Turning This Cable Maker Into a Stock to Watch
• A Star Investor Just Trimmed Amazon—Here's What It means
• Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
• Home Depot Analysts See a Path to $375 and Beyond

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in OrthoPediatrics Right Now?

Before you consider OrthoPediatrics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.

While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here